Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.